Advice

following an abbreviated submission:

pertuzumab/trastuzumab (Phesgo®) is accepted for restricted use within NHSScotland.

Indication under review:

Early breast cancer (EBC)
In combination with chemotherapy in:

  • the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence
  • the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence

Metastatic breast cancer (MBC)
In combination with docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.

SMC restriction: Restricted to use in line with previous SMC advice for pertuzumab and trastuzumab (see SMC2284; SMC2120; SMC2119; SMC No. 928/13; SMC No. 278/06).

Pertuzumab/trastuzumab (Phesgo®) provides a combination injection for subcutaneous use.

Pertuzumab has previously been accepted by SMC under the orphan medicine process.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/list price that is equivalent or lower.

Download detailed advice651KB (PDF)

Download

Medicine details

Medicine name:
pertuzumab and trastuzumab (Phesgo)
SMC ID:
SMC2364
Indication:

Early breast cancer (EBC)
In combination with chemotherapy in:
• the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence
• the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence

Metastatic breast cancer (MBC)
In combination with docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.

Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Abbreviated
Status
Restricted
Date advice published
12 July 2021